Advisory Committee Policy Allows Members With Financial Conflicts To Vote
• By Brian Marson
FDA advisory committee participants with personal financial conflicts of interest may fully participate in committee meetings, according to the agency's new conflict of interest policy. The final guidance eliminates the draft provision that financial conflicts of any sort preclude an opportunity for panelists to vote
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.